Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
- Herbst RS, Tsuboi M, John T, et al. Osimertinib as adjuvant therapy in patients with stage IB-IIIA EGFR mutation positive NSCLC after complete tumor resection: ADAURA. J Clin Oncol. 2020;38(suppl 18):LBA5.
- Tsuboi M, Wu Y, He J, et al. Osimertinib adjuvant therapy in patients with resected EGFR mutated NSCLC (ADAURA): central nervous system (CNS) disease recurrence. Ann Oncol. 2020;31(suppl 4):S1142-S1215.
- Wu Y-L, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383(18):1711-1723.
Disclosure statements are available on the authors' profiles: